OPS-2071
Phase 2Small molecule
OtsukaOPS-2071 is one of 41 small molecule programs targeting Irritable Bowel Syndrome. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
185 competitors in Irritable Bowel Syndrome
#DrugCompanyPhaseTrials
1Lialda
TakedaPhase 3
Xifaxan
SSalix
Phase 3
Zofran
NovartisPhase 3
Amitiza
SSucampo Pharma Americas, LLC
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Zarontin
PParkedale
Phase 3
Mesalazine
FerringPhase 3
Saccharomyces Boulardii
BBiocodex
Phase 3
Trulance
SSalix
Phase 3
Lotronex
LLegacy Health System
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Irritable Bowel Syndrome1 trial
Enteritis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OPS-2071. EMBL-EBI & Wellcome Sanger Institute.
- [4]